
## Massimo Siciliano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11313580/publications.pdf Version: 2024-02-01



MASSIMO SICILIANO

#	Article	IF	CITATIONS
1	Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project. Journal of Viral Hepatitis, 2021, 28, 651-656.	1.0	5
2	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. Digestive Diseases, 2020, 38, 522-533.	0.8	7
3	Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. Annals of Hepatology, 2019, 18, 434-438.	0.6	8
4	Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?. European Journal of Radiology, 2019, 114, 32-37.	1.2	8
5	ACE I allele is associated with more severe portal hypertension in patients with liver cirrhosis: A pilot study. Digestive and Liver Disease, 2019, 51, 293-296.	0.4	6
6	Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2018, 19, 1941-1948.	0.9	17
7	Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infectious Diseases, 2018, 18, 223.	1.3	19
8	Lack of reduction in serum alphaâ€fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virusâ€related cirrhosis. Journal of Viral Hepatitis, 2018, 25, 1493-1500.	1.0	6
9	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy. Scientific Reports, 2018, 8, 8988.	1.6	36
10	Daclatasvir, Sofosbuvir With or Without Ribavirin for 24 Weeks In Hepatitis C Genotype 3 Cirrhosis: A Real-Life Study. Annals of Hepatology, 2018, 17, 0-10.	0.6	0
11	Multiclass <scp>HCV</scp> resistance to directâ€acting antiviral failure in realâ€life patients advocates for tailored secondâ€line therapies. Liver International, 2017, 37, 514-528.	1.9	84
12	â€~Hug sign': a new radiological sign of intraprocedural success after combined treatment for hepatocellular carcinoma. Hepatic Oncology, 2017, 4, 69-73.	4.2	4
13	Liver Resection versus Radiofrequency Ablation plus Transcatheter Arterial Chemoembolization in Cirrhotic Patients with Solitary Large Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, 1512-1519.	0.2	26
14	Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A realâ€ <del>li</del> fe study. Liver International, 2017, 37, 653-661.	1.9	13
15	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS ONE, 2017, 12, e0177352.	1.1	13
16	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World Journal of Hepatology, 2017, 9, 352.	0.8	50
17	Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Digestive and Liver Disease, 2015, 47, 242-248.	0.4	53
18	A pilot study of capsule endoscopy after a standard meal for the detection and grading of oesophageal varices in cirrhotic patients. Digestive and Liver Disease, 2014, 46, 997-1000.	0.4	2

MASSIMO SICILIANO

#	Article	IF	CITATIONS
19	Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. World Journal of Gastroenterology, 2013, 19, 3255.	1.4	6
20	Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: Preliminary data. Journal of the American Academy of Dermatology, 2010, 62, 1067-1069.e2.	0.6	25
21	Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. Journal of Hepatology, 2007, 46, 206-212.	1.8	188
22	Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. Journal of the American Academy of Dermatology, 2006, 54, 1102-1104.	0.6	43
23	Erythropoietin secretion in patients with liver cirrhosis. Scandinavian Journal of Gastroenterology, 2005, 40, 122-123.	0.6	2
24	Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology, 1995, 22, 1132-1135.	3.6	29